FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
|Slideshows|October 22, 2018
Low Leptin Receptors and PCOS: What’s the Link?
Author(s)Gregory M. Weiss, MD
Listen
0:00 / 0:00
Leptin resistance may be responsible for elevated leptin levels in obese women with polycystic ovary syndrome, according to authors of this study.
Advertisement
Reference: Hahn S, Haselhorst U, Quadbeck B, et al. Decreased soluble leptin receptor levels in women with polycystic ovary syndrome. Eur J Endocrinol. 2006;154:287-294.Â
Advertisement
Related to this article
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Advertisement
Advertisement
Trending on HCPLive
1
EADV Congress 2026: Day 3 Recap—5 Headlines to Know
2
Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD
3
8 Pulmonology Headlines You Missed in Q3 2026
4
EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis
5